Objective: To define molecular mechanisms underlying the clinical spectrum of epilepsy and movement disorder in individuals with de novo mutations in the GNAO1 gene.
Epilepsy is one of the most common neurologic disorders in the United States. 1 Severe earlyonset seizures can result in epileptic encephalopathy. 2 There are at least 52 different gene mutations that cause early infantile epileptiform encephalopathy (EIEE). 3 Mutations in the same genes also cause other neurodevelopmental abnormalities. 4, 5 A key challenge in genetic epilepsies has been understanding the genotype-phenotype relationships of causal genes; this may require biochemical analysis. 6 Mutations in the heterotrimeric G protein Ga o (GNAO1 gene) cause an autosomal dominant epileptiform encephalopathy (EIEE17, OMIM: 615473). 7 In this original article, all 4 mutations were characterized as having loss of function (LOF). 7 More recently, an extended spectrum of GNAO1 encephalopathies was identified in which individuals had movement disorders but minimal to no seizures. 8, 9 Here, we use GNAO1 encephalopathy to describe the entire clinical spectrum of individuals with pathologic GNAO1 mutations. A genotype-phenotype correlation was also recently noted 10 ; certain mutations (e.g., E246K and several R209 alleles) were found specifically in children with hypotonia, developmental delay, and chorea but no epilepsy. However, the mechanistic basis for this genotype-phenotype correlation remains unknown.
GNAO1 encodes the a subunit of G o , a heterotrimeric G protein (consisting of a and bg subunits) that is highly abundant in the CNS, comprising about 1% of brain membrane protein. 11 G o mediates signals from a wide range of inhibitory receptors including GABA B , a 2A adrenergic, adenosine A 1 , and dopamine D 2 receptors. A canonical function of Ga i/o family proteins is inhibition of cyclic adenosine monophosphate (cAMP). 12 The identification of GOF mutations in ADCY5 (which encodes adenylate cyclase 5, the enzyme that produces cAMP) in dyskinesia and chorea patients directly links reduced cAMP to involuntary movement disorders. [13] [14] [15] [16] [17] This is consistent with GOF behavior of Ga o .
Here we assessed expression and function of human mutations in GNAO1. [7] [8] [9] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Our biochemical analysis identified both LOF and gain-of-function (GOF) behaviors; the latter are associated with movement disorders while the former are primarily found in individuals with epileptiform encephalopathies. This mechanistic insight has important implications for therapies of GNAO1 encephalopathies.
METHODS The detailed sources of reagents and antibodies, and the methods for mutagenesis, cell culture, transfections, Western blot, and cAMP assays, are described in the e-Methods at Neurology.org. The primer sets used in this study are listed in Location and protein expression levels of human GNAO1 mutations related to epileptic encephalopathy (A) Location of 15 mutations (G40R, G42R, D174G, T191_F197del, L199P, G203R, R209C, R209G, R209H, A227V,  Y231C, E246K, previously identified in patients with epilepsy or other neurodevelopmental disorders, 7-9,18-27 we performed Western blots in HEK-293T cells transiently transfected with each mutant. The majority of mutants (12) showed significantly lower protein levels than wild-type (WT) Ga o , whereas 3 separate Arg 209 mutant alleles showed essentially normal expression, as did the previously described GOF mutant G184S 28 ( figure 1, B 
-E).
Validation of an in vitro assay to assess function of GNAO1 mutations. We used inhibition of forskolinstimulated cAMP levels as a functional readout to allow efficient quantification of Ga o effects with full concentration curves for agonist-mediated signaling. We cotransfected Ga o plasmids with a 2A adrenergic receptor (a 2A AR) cDNA. 29 Robust inhibition of cAMP by the a 2 adrenergic agonist UK14,304 depends on both the transfected receptor and the Ga o protein (figure e-2, A and B). A pertussis toxin (PTX)-insensitive Ga o (C351G) 30 was used to create all mutant constructs and WT, enabling inactivation of endogenous G i/o proteins using PTX.
When PTX eliminates the inhibitory signaling through G i/o , a 2A AR couples weakly to G s and stimulates adenylate cyclase (AC), 31 resulting in increased cAMP levels after PTX treatment in the absence of a transfected Ga o (figure e-2B). Consequently, the fractional inhibition of AC by Ga o mutants was assessed as the decrease from the high control level of cAMP (PTX but no Ga o -0%) to the low level with WT Ga o (PTX and PTXi Ga o -100%). This is termed normalized % inhibition. PTX treatment did not alter the ability of the PTX-insensitive Ga o to mediate a 2A ARstimulated cAMP inhibition (figure e-2C). Hence, this is a good system to study functional consequences of Ga o mutations.
Nine GNAO1 mutations result in LOF or partial LOF.
Six mutants showed essentially complete LOF with normalized inhibition below 40% ( figure 2A and  table 1 ). All of these mutants also showed low expression levels (11%-35% of control; figure 1 ). Three mutants (A227V, Y231C, and I279N; figure 2, A and E, and table 1) had intermediate effects and were classified as partial LOF (PLOF) mutants. The I279N mutation showed a modestly reduced maximal inhibition of cAMP levels (figure 2E and table 1 ). This mutant also produced a very low EC 50 value (0.7 nM vs 25 nM for WT Ga o ), which might explain the discrepancy between the low expression levels (15% of WT) while maintaining good maximal inhibition in the cAMP inhibition assay. Based on the maximum inhibition below 90% of control, however, we classified this mutation as PLOF (table 1) .
The dominant nature of the clinical picture in the GNAO1 encephalopathies raised the question of whether the LOF mutations are actually dominant negative mutations that interfere with the function of the remaining normal Ga o protein expressed in heterozygous individuals. However, in coexpression studies of WT and mutant Ga o at plasmid ratios of 1:1 or 1:2, there was no evidence of a dominant negative action (figure e-3). This suggests that the effect of LOF mutations is through a haploinsufficiency mechanism rather than a dominant negative one.
Six GNAO1 mutations result in GOF or normal function.
Unexpectedly, a significant number of pathologic GNAO1 mutants showed essentially normal or even GOF behavior (figure 2, B-E, and table 2). As a benchmark for GOF behavior, we used our previously described RGS-insensitive G184S mutant, 28, 29, 32, 33 which shows a mild seizure phenotype in mouse models. 32 It produced a small increase in the maximum inhibition of forskolin-stimulated cAMP levels in response to UK14,304 (table 2) . More importantly, it had a significantly more potent response to the a 2 AR agonist UK14,304 (figures 2D and e-4A). This represents a 2-to 3-fold increase in signal strength at low agonist concentrations. Three of the human pathologic GNAO1 mutants also showed GOF behavior by this criterion. The G203R, E246K, and G42R mutants produced robust inhibition of cAMP with significantly lower EC 50 values for the a 2 AR agonist UK14,304 (figures 2D and e-4, and table 2). G203R and E246K showed normal inhibition with modest decreases in EC 50 (table 2 and figures 2, D and E, and e-4). This is similar to the effect on EC 50 seen for the bona fide GOF mutant G184S. The G42R mutant showed the lowest EC 50 of any of the mutants (figure e-4), at least 50-fold lower than the WT protein (figure 2, C and D). However, the inhibition mediated by G42R is followed by activation of cAMP with increasing concentrations of UK14,304 (figure 2C). The calculated normalized % inhibition for the G42R mutant is essentially identical to that of WT Ga o , which combined with its very high potency for agonistmediated inhibition suggests GOF behavior.
Three other patient-derived mutations (R209G, R209H, and R209C) showed almost completely normal function (NF) and nearly normal expression levels and are designated as NF mutants (figures 2, B, D, and E, and e-4, and table 2). The EC 50 values for R209G and R209H mutant were not significantly different from WT, while the value for R209C was modestly but significantly higher (table 2 and figures 2D and e-4).
Clinical correlation with biochemical behavior of mutant GNAO1 alleles. To address genotype-phenotype correlations for GNAO1 encephalopathy, we reviewed the case reports of all 25 individuals who had GNAO1 mutations that had been reported by April 2016. They have a range of clinical patterns, which extend from early severe epileptic encephalopathy with prominent tonic seizure activity to individuals with a dominant choreoathetotic movement disorder with virtually no evidence of seizures. There are also individuals, 18, 21 including one of the original 4 cases 7 (patient 13-G203R; table 3), who had multiple seizures but also showed prominent choreoathetosis.
In 2016, a clinical report 9 described a series of 6 patients with GNAO1 mutations and a pronounced movement disorder, virtually without seizures. They had global developmental delay and hypotonia from infancy and all developed chorea by ages 4-11 years. In the majority of cases it was intractable, leading to death in 2 cases. Four patients carried the E246K allele, which we have found to be a GOF mutation. The other 2 mutations found in this group (R209G and R209C) exhibited essentially normal function in our cAMP inhibition measurements. There are several other reports 8, 9, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] of GNAO1 mutations in individuals with a predominant movement disorder with or without seizures. This distinction of clinical patterns based on certain mutant alleles in GNAO1 encephalopathy patients was noted very recently 10 but without information about biochemical mechanisms. Table 3 summarizes the Ga o biochemical function from the present report and its relation to seizure disorder or movement disorder in literature reports for these mutations. GOF and NF mutations are nearly always found when movement disorder is the predominant feature of the clinical pattern. Mutations that have pure LOF or PLOF biochemical phenotypes are seen in individuals with epileptic encephalopathy without pronounced choreoathetosis. A number of patients exhibit both seizures and movement disorder. We have indicated in table 3 with major symptoms or minor symptoms which of these features is predominant or less so. Further studies will be needed based on new cases or additional mutations, but there does appear to be a clear pattern emerging about a genotype-phenotype correlation that is driven by a GOF/LOF difference in mutant GNAO1 alleles. biochemical analysis will provide definitive understanding of function.
DISCUSSION The concept of a GNAO1 encephalopathy has developed based on the identification of at least 15 different mutations in the GNAO1 gene 7-9,18-27 associated with various combinations of epilepsy, developmental delay, hypotonia, and choreoathetotic movement disorders. Our study demonstrates GOF as well as LOF mutations in GNAO1 and describes a clear correlation between biochemical and clinical characteristics. The existence of these unexpected GOF mutations has important therapeutic implications. Specifically, one might expect that different approaches to therapy would be needed for different mutations (i.e., agonists for LOF and antagonists for GOF mutants).
We chose inhibition of cAMP production as the functional readout to assess the Ga o mutants because of the robust measurements permitting complete agonist concentration response studies. This was critical to our findings since the GOF mutants were detected primarily through their ability to increase signals at low agonist concentrations ( figure 2 and table 2 ). Our previously studied GOF mutant (G184S), which is insensitive to the inhibitory influence of RGS proteins, shows such a left shift of agonist concentration response curves in vitro 28, 34 and in vivo 29, 35 and also has a mild seizure phenotype in a mouse model. 32 One might argue that cAMP is not the best choice of functional measures for epilepsy since N-type Ca 11 channels or the synaptic release mechanism proteins are critical for regulation of neurotransmitter release. However, the apparent correlation of clinical patterns with the biochemical behavior in our cAMP assay suggests that function assessed in this way is relevant to functionality in humans. The clear pathologic effect of Table 3 Correlation between cyclic adenosine monophosphate (cAMP) inhibition and clinical diagnosis A dominant genetic effect from GOF mutants is not unusual but the fact that the LOF mutations result in a severe autosomal dominant disorder is a bit surprising. We have ruled out a biochemical dominant negative mechanism of these mutations, at least for cAMP regulation, suggesting a haploinsufficiency mechanism. In mice, homozygous Ga o 2/2 knockouts exhibit seizures as well as hyperactive turning behavior. 36 We did not, however, observe spontaneous seizures or an increased sensitivity to pentylenetetrazol kindling in heterozygous Ga o 1/2 knockouts. 32 This suggests that humans are more susceptible to haploinsufficiency of Ga o than are mice. In contrast, we observed enhanced kindling sensitivity and reduced survival in our Gnao1 1/G184S knock-in mouse model possibly due to seizures. 32 Furthermore, these mice display early neonatal lethality 32 of unclear mechanism, which may be similar to the hypotonia seen in human patients carrying GOF mutations. We do not know whether the abnormalities in these mice are due to brain developmental abnormalities or acute signaling effects. Further studies are needed to better understand this and to determine whether our Ga o 1/G184S mutant mouse might represent a useful preclinical model for individuals with GNAO1 GOF mutations.
To date, all characterized GNAO1 mutants have been reported as LOF mutations. The G203R mutant in the original article 7 was reported as a LOF mutant for regulation of N-type Ca 11 channels. Similarly, a G42R mutation in Ga i1 was reported as a LOF mutant based on biochemical studies. 37 The unique approach that we have taken with detailed cAMP dose-response studies in a mammalian cell model permitted our recognition of the GOF mechanisms (e.g., the Ga o G42R mutation). The patient with the G203R mutation, which we found to have GOF for cAMP inhibition, had a very different clinical pattern than the other 3 patients in the original study. 7 She had a much later onset of disease (7 months) as well as developmental delay and severe chorea with only localized seizures. 7 A similar clinical pattern was observed in 2 more recently described patients with this same mutation. 18, 21 All patients carrying the GOF mutations identified here appear distinct from the strict EIEE pattern (table 3) . In comparison, patients with LOF or PLOF mutations were diagnosed with either Ohtahara syndrome (Y231C, I279N, D174G, T191_F197del) or EIEE (A227V, L199P, N270H, F275S). Thus GOF and LOF mutations in Ga o appear to result in different disease mechanisms likely requiring different therapeutic approaches.
It has remained challenging to convert knowledge about genetic epilepsy mutations into therapies. The GNAO1 encephalopathies may be different because of the eminently druggable nature of the receptors that drive Ga o signaling pathways. A critical question then becomes which receptors might be involved. Interestingly, activation of many G i/o -coupled receptors is associated with suppression of seizures. Adenosine A1 receptors may play a role in the efficacy of the ketogenic diet 38 and agonists at group II metabotropic glutamate receptors are anticonvulsant in various models. 39 The opposite situation is also seen; GABA B R agonists exacerbate absence seizures while GABA B R antagonists suppress them. 40 Identifying which receptors or downstream signaling effectors of Ga o contribute to mechanisms of encephalopathy from LOF or GOF GNAO1 mutations could therefore reveal potential targets for novel anticonvulsant drug development.
We have identified distinct biochemical mechanisms of pathogenic human GNAO1 mutations that may improve the understanding of the heterogeneous clinical spectrum of GNAO1-associated epilepsy and movement disorders. Furthermore, these results also carry significant implications for personalized therapeutics in GNAO1 encephalopathies.
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